Literature DB >> 16677934

Effect of 5-fluorouracil, Optison and ultrasound on MCF-7 cell viability.

Olga V Chumakova1, Anton V Liopo, B Mark Evers, Rinat O Esenaliev.   

Abstract

The aim of this study was to analyze cell viability and expression of apoptotic-related signaling proteins in MCF-7 breast cancer cells induced by combinations of ultrasound, the anticancer drug 5-fluorouracil (5-FU) and the ultrasound contrast agent Optison. MCF-7 cells were treated with 5-FU and sonicated at the frequency of 3.0 MHz and intensity of 3.0 W/cm2 for 1 min in the presence of Optison. The cells were analyzed for lactate dehydrogenase (LDH) release (a measure of cytotoxicity) and cell proliferation (by MTT assays). The LDH/MTT ratio was used for assessment of cell death. Expression of the apoptotic-related proteins, Bax and p27kip1, as well as phosphorylated forms of ERK and Akt proteins was assessed by Western blot analysis. We demonstrate that, immediately after treatment, cell death was most dependent on Optison; however, 24 h after treatment, cell death was more dependent on 5-FU. Ultrasound duty cycle increased cell death associated with either Optison or 5-FU. Furthermore, we show that treatment with 5-FU and ultrasound increased the levels of the Bax and p27kip1 proteins, but the addition of Optison appears to suppress apoptotic protein expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677934     DOI: 10.1016/j.ultrasmedbio.2006.01.011

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  10 in total

Review 1.  A review of low-intensity ultrasound for cancer therapy.

Authors:  Andrew K W Wood; Chandra M Sehgal
Journal:  Ultrasound Med Biol       Date:  2015-04       Impact factor: 2.998

2.  Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.

Authors:  Caitlin W Burke; Eben Alexander; Kelsie Timbie; Alexander L Kilbanov; Richard J Price
Journal:  Mol Ther       Date:  2013-10-31       Impact factor: 11.454

3.  The induction of the apoptosis of cancer cell by sonodynamic therapy: a review.

Authors:  Wen-Kun Bai; E Shen; Bing Hu
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  Highly purified biocompatible gold nanorods for contrasted optoacoustic imaging of small animal models.

Authors:  Anton V Liopo; André Conjusteau; Olga V Chumakova; Sergey A Ermilov; Richard Su; Alexander A Oraevsky
Journal:  Nanosci Nanotechnol Lett       Date:  2012-07

5.  A frequency-based hypothesis for mechanically targeting and selectively attacking cancer cells.

Authors:  M Fraldi; A Cugno; L Deseri; K Dayal; N M Pugno
Journal:  J R Soc Interface       Date:  2015-10-06       Impact factor: 4.118

Review 6.  Microbubbles Stabilized by Protein Shell: From Pioneering Ultrasound Contrast Agents to Advanced Theranostic Systems.

Authors:  Polina G Rudakovskaya; Roman A Barmin; Pavel S Kuzmin; Elena P Fedotkina; Alexander N Sencha; Dmitry A Gorin
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

7.  Biocompatible Gold Nanorod Conjugates for Preclinical Biomedical Research.

Authors:  Anton Liopo; André Conjusteau; Dmitri Tsyboulski; Boris Ermolinsky; Alexander Kazansky; Alexander Oraevsky
Journal:  J Nanomed Nanotechnol       Date:  2012-08-03

8.  PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors.

Authors:  Marxa Figueiredo; Rinat Esenaliev
Journal:  J Drug Deliv       Date:  2012-02-28

9.  Combined treatment of PC-3 cells with ultrasound and microbubbles suppresses invasion and migration.

Authors:  Cong Wei; Wen-Kun Bai; Yu Wang; Bing Hu
Journal:  Oncol Lett       Date:  2014-07-03       Impact factor: 2.967

10.  Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.

Authors:  Zheng Hu; Guixiang Lv; Yongning Li; Enze Li; Haixia Li; Qi Zhou; Bin Yang; Wenwu Cao
Journal:  J Exp Clin Cancer Res       Date:  2016-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.